A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
Status:
Completed
Trial end date:
2024-02-20
Target enrollment:
Participant gender:
Summary
This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a
perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of
JAB-21822 as a victim combined with itraconazole， rifampicin， and omeprazole in healthy
subjects.